Additional lock-up agreements have been signed by Chairman of the board and management
DanCann Pharma A/S (” DanCann Pharma” or the “Company”) hereby announces that additional board members and management have been allotted units in the IPO. DanCann Pharma’s Chairman of the Board, Magnus Østergaard Dahlmann, Chief Commercial Officer, John Morell Frellsen (who works for the Company as a consultant and is thereby not part of the Company’s registered executive management) and Chief Financial Officer, Mads Møller Kristensen (’the “Subscribers’’) that subscribed for units in the fully subscribed IPO have now been allotted units after the subscription period ended on October 23rd 2020. As communicated the Subscribers have agreed to sign a lock-up agreement for 12 months after the first day of trading at Spotlight Stock Market Denmark.
The preliminary date for listing of DanCann Pharma’s shares and warrants on the Spotlight Stock Market is November 12th, 2020.
Compilation of lock-up from the board, management, and other shareholders
In total, the lock-up from the board, management, and shareholders after the fully subscribed IPO amount to 8 221 565 shares, corresponding to approximately 39,66%, and are distributed according to the table below.
| Name | Number of shares | |
| JKR Investment Group ApS (Jeppe Krog Rasmussen, CEO, Founder, and Board Member) | 5 280 000 | |
| JJV Invest AB | 1 600 000 | |
| Morten Martinsen (COO) | 400 000 | |
| Hansen & Nytoft Invest ApS | 300 000 | |
| VaVi Invest ApS | 198 000 | |
| JBJensen ApS | 120 000 | |
| Per Wester (Board Member) | 112 950 | |
| HeRoed ApS | 102 000 | |
| John Morell Frellsen (CCO) | 58 890 | |
| Magnus Østergaard Dahlmann (Chairman) | 22 500 | |
| C-Plus Consult (Carsten Trads, Board Member) | 22 225 | |
| Mads Møller Kristensen (CFO) | 5 000 | |
| Total | 8 221 565 | |
About DanCann Pharma
DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
For further information, please contact:
Jeppe Krog Rasmussen, CEO
Email: jkr@dancann.com
Website: www.dancann.com
For additional information regarding the IPO of units, please contact:
Corpura Fondkommission AB
Email: info@corpura.se